Skip to main content

Mylan to Commercialize Atomo Dx HIV Self-Tests in Low-, Middle-Income Nations

NEW YORK (360Dx) — Atomo Diagnostics has signed an agreement to commercialize its CE-marked HIV self-tests in low- and middle-income nations with Mylan Pharmaceuticals, the companies announced today.

Atomo's tests use the firm's AtomoRapid technology to detect the presence of HIV antibodies from a finger prick of blood and provides results within 15 minutes.

Under the terms of the deal, Mylan — which markets a number of HIV drugs and combination therapies — has the exclusive rights to commercialize the tests in more than 100 countries in Africa, Asia, the Middle East, the Commonwealth of Independent States, and Latin America. Additional terms were not disclosed.

The Mylan HIV Self-Test is expected to launch globally in early 2019.

"This strategic partnership will mean that the products designed by Atomo can be introduced to more than 100 countries, so that millions of people will have access to award-winning rapid tests," Atomo Founder and CEO John Kelly said in a statement.

Earlier this year, Sydney-based Atomo licensed the exclusive rights to its HIV self tests in Europe to Owen Mumford.